|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CYP7B1 |
Gene summary for CYP7B1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CYP7B1 | Gene ID | 9420 |
| Gene name | cytochrome P450 family 7 subfamily B member 1 | |
| Gene Alias | CBAS3 | |
| Cytomap | 8q12.3 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q05C57 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 9420 | CYP7B1 | NAFLD1 | Human | Liver | NAFLD | 7.74e-06 | 7.32e-01 | -0.04 |
| 9420 | CYP7B1 | S41 | Human | Liver | Cirrhotic | 6.52e-07 | 5.96e-01 | -0.0343 |
| 9420 | CYP7B1 | S43 | Human | Liver | Cirrhotic | 2.61e-02 | 2.11e-01 | -0.0187 |
| 9420 | CYP7B1 | HCC1_Meng | Human | Liver | HCC | 8.28e-51 | 4.79e-03 | 0.0246 |
| 9420 | CYP7B1 | HCC2_Meng | Human | Liver | HCC | 1.51e-07 | -9.87e-02 | 0.0107 |
| 9420 | CYP7B1 | cirrhotic1 | Human | Liver | Cirrhotic | 3.36e-02 | -1.13e-01 | 0.0202 |
| 9420 | CYP7B1 | Pt13.b | Human | Liver | HCC | 1.52e-02 | -1.67e-02 | 0.0251 |
| 9420 | CYP7B1 | S016 | Human | Liver | HCC | 9.85e-08 | 2.91e-01 | 0.2243 |
| 9420 | CYP7B1 | S028 | Human | Liver | HCC | 5.93e-05 | 2.57e-01 | 0.2503 |
| 9420 | CYP7B1 | S029 | Human | Liver | HCC | 3.15e-04 | 2.55e-01 | 0.2581 |
| 9420 | CYP7B1 | RNA-P25T1-P25T1-1 | Human | Lung | AIS | 1.67e-11 | 5.31e-01 | -0.2116 |
| 9420 | CYP7B1 | RNA-P25T1-P25T1-3 | Human | Lung | AIS | 9.09e-03 | 4.46e-01 | -0.2107 |
| 9420 | CYP7B1 | RNA-P25T1-P25T1-4 | Human | Lung | AIS | 2.81e-06 | 4.57e-01 | -0.2119 |
| 9420 | CYP7B1 | RNA-P3T-P3T-1 | Human | Lung | IAC | 1.44e-06 | 4.94e-01 | 0.1829 |
| 9420 | CYP7B1 | RNA-P3T-P3T-2 | Human | Lung | IAC | 2.34e-05 | 4.93e-01 | 0.1835 |
| 9420 | CYP7B1 | RNA-P3T-P3T-4 | Human | Lung | IAC | 3.36e-05 | 4.67e-01 | 0.1859 |
| 9420 | CYP7B1 | RNA-P6T2-P6T2-1 | Human | Lung | IAC | 4.20e-04 | 2.36e-01 | -0.0166 |
| 9420 | CYP7B1 | RNA-P6T2-P6T2-2 | Human | Lung | IAC | 1.53e-07 | 3.04e-01 | -0.0132 |
| 9420 | CYP7B1 | RNA-P6T2-P6T2-3 | Human | Lung | IAC | 1.43e-02 | 1.73e-01 | -0.013 |
| 9420 | CYP7B1 | RNA-P6T2-P6T2-4 | Human | Lung | IAC | 1.62e-06 | 3.04e-01 | -0.0121 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00160535 | Liver | NAFLD | organic acid biosynthetic process | 77/1882 | 316/18723 | 1.03e-13 | 6.69e-11 | 77 |
| GO:00463945 | Liver | NAFLD | carboxylic acid biosynthetic process | 75/1882 | 314/18723 | 6.37e-13 | 3.39e-10 | 75 |
| GO:00485457 | Liver | NAFLD | response to steroid hormone | 75/1882 | 339/18723 | 3.44e-11 | 1.12e-08 | 75 |
| GO:00082023 | Liver | NAFLD | steroid metabolic process | 69/1882 | 319/18723 | 5.90e-10 | 1.28e-07 | 69 |
| GO:00550883 | Liver | NAFLD | lipid homeostasis | 44/1882 | 167/18723 | 1.48e-09 | 2.54e-07 | 44 |
| GO:00713836 | Liver | NAFLD | cellular response to steroid hormone stimulus | 48/1882 | 204/18723 | 1.50e-08 | 1.83e-06 | 48 |
| GO:0008206 | Liver | NAFLD | bile acid metabolic process | 19/1882 | 49/18723 | 9.82e-08 | 7.76e-06 | 19 |
| GO:00305226 | Liver | NAFLD | intracellular receptor signaling pathway | 55/1882 | 265/18723 | 1.39e-07 | 1.03e-05 | 55 |
| GO:00723303 | Liver | NAFLD | monocarboxylic acid biosynthetic process | 46/1882 | 214/18723 | 5.06e-07 | 3.07e-05 | 46 |
| GO:00426323 | Liver | NAFLD | cholesterol homeostasis | 26/1882 | 96/18723 | 1.83e-06 | 7.86e-05 | 26 |
| GO:00550923 | Liver | NAFLD | sterol homeostasis | 26/1882 | 97/18723 | 2.26e-06 | 9.51e-05 | 26 |
| GO:0008203 | Liver | NAFLD | cholesterol metabolic process | 32/1882 | 137/18723 | 4.28e-06 | 1.66e-04 | 32 |
| GO:0006699 | Liver | NAFLD | bile acid biosynthetic process | 14/1882 | 36/18723 | 4.59e-06 | 1.75e-04 | 14 |
| GO:0016125 | Liver | NAFLD | sterol metabolic process | 34/1882 | 152/18723 | 6.02e-06 | 2.11e-04 | 34 |
| GO:1902652 | Liver | NAFLD | secondary alcohol metabolic process | 33/1882 | 147/18723 | 7.57e-06 | 2.56e-04 | 33 |
| GO:00060666 | Liver | NAFLD | alcohol metabolic process | 62/1882 | 353/18723 | 9.01e-06 | 2.96e-04 | 62 |
| GO:00097556 | Liver | NAFLD | hormone-mediated signaling pathway | 39/1882 | 190/18723 | 1.15e-05 | 3.58e-04 | 39 |
| GO:00066943 | Liver | NAFLD | steroid biosynthetic process | 34/1882 | 173/18723 | 1.01e-04 | 2.02e-03 | 34 |
| GO:00434016 | Liver | NAFLD | steroid hormone mediated signaling pathway | 28/1882 | 136/18723 | 1.78e-04 | 3.14e-03 | 28 |
| GO:00487327 | Liver | NAFLD | gland development | 67/1882 | 436/18723 | 2.83e-04 | 4.53e-03 | 67 |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa00120 | Liver | NAFLD | Primary bile acid biosynthesis | 9/1043 | 17/8465 | 6.10e-05 | 1.33e-03 | 1.07e-03 | 9 |
| hsa001201 | Liver | NAFLD | Primary bile acid biosynthesis | 9/1043 | 17/8465 | 6.10e-05 | 1.33e-03 | 1.07e-03 | 9 |
| hsa001202 | Liver | HCC | Primary bile acid biosynthesis | 14/4020 | 17/8465 | 3.49e-03 | 1.12e-02 | 6.22e-03 | 14 |
| hsa001203 | Liver | HCC | Primary bile acid biosynthesis | 14/4020 | 17/8465 | 3.49e-03 | 1.12e-02 | 6.22e-03 | 14 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CYP7B1 | SNV | Missense_Mutation | c.533C>A | p.Ala178Glu | p.A178E | O75881 | protein_coding | tolerated(1) | benign(0.003) | TCGA-AQ-A04J-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
| CYP7B1 | SNV | Missense_Mutation | c.602N>C | p.Ile201Thr | p.I201T | O75881 | protein_coding | tolerated(0.62) | benign(0.001) | TCGA-BH-A0RX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | SD | |
| CYP7B1 | SNV | Missense_Mutation | novel | c.1085N>C | p.Leu362Pro | p.L362P | O75881 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-BH-A1FU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
| CYP7B1 | SNV | Missense_Mutation | novel | c.946N>A | p.Ala316Thr | p.A316T | O75881 | protein_coding | tolerated(0.14) | benign(0.292) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| CYP7B1 | SNV | Missense_Mutation | novel | c.376N>C | p.Ser126Arg | p.S126R | O75881 | protein_coding | tolerated(0.06) | benign(0.038) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| CYP7B1 | SNV | Missense_Mutation | c.922N>T | p.Leu308Phe | p.L308F | O75881 | protein_coding | deleterious(0.01) | possibly_damaging(0.706) | TCGA-EA-A3HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| CYP7B1 | insertion | Frame_Shift_Ins | rs747514385 | c.314_315insA | p.Asn105LysfsTer3 | p.N105Kfs*3 | O75881 | protein_coding | TCGA-XS-A8TJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD | ||
| CYP7B1 | SNV | Missense_Mutation | c.955N>T | p.Arg319Cys | p.R319C | O75881 | protein_coding | deleterious(0) | probably_damaging(0.977) | TCGA-A6-5665-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| CYP7B1 | SNV | Missense_Mutation | novel | c.967N>T | p.Asp323Tyr | p.D323Y | O75881 | protein_coding | tolerated(0.1) | probably_damaging(0.916) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| CYP7B1 | SNV | Missense_Mutation | novel | c.1315N>A | p.Leu439Ile | p.L439I | O75881 | protein_coding | tolerated(0.2) | benign(0.119) | TCGA-AA-3811-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 9420 | CYP7B1 | ENZYME, DRUGGABLE GENOME, CYTOCHROME P450 | DIAZOXIDE | DIAZOXIDE | 8301566 | |
| 9420 | CYP7B1 | ENZYME, DRUGGABLE GENOME, CYTOCHROME P450 | MITOMYCIN-C | 8162589 | ||
| 9420 | CYP7B1 | ENZYME, DRUGGABLE GENOME, CYTOCHROME P450 | ACETAMINOPHEN | ACETAMINOPHEN | 2242029 | |
| 9420 | CYP7B1 | ENZYME, DRUGGABLE GENOME, CYTOCHROME P450 | ADRIAMYCIN | ADRIAMYCIN | 8162589 | |
| 9420 | CYP7B1 | ENZYME, DRUGGABLE GENOME, CYTOCHROME P450 | ANTI-DIABETIC AGENT | 15207658 | ||
| 9420 | CYP7B1 | ENZYME, DRUGGABLE GENOME, CYTOCHROME P450 | DDD | 7587937 | ||
| 9420 | CYP7B1 | ENZYME, DRUGGABLE GENOME, CYTOCHROME P450 | SAPONIN | 9342944 | ||
| 9420 | CYP7B1 | ENZYME, DRUGGABLE GENOME, CYTOCHROME P450 | GINKGO | GINKGO | 15901353 | |
| 9420 | CYP7B1 | ENZYME, DRUGGABLE GENOME, CYTOCHROME P450 | SR 4233 | 8461036 | ||
| 9420 | CYP7B1 | ENZYME, DRUGGABLE GENOME, CYTOCHROME P450 | LYCOPENE | LYCOPENE | 14640578 |
| Page: 1 2 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |